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Abstract
Background: G6PD deficiency is common in malaria endemic regions and is estimated to affect more than 400
million people worldwide. Treatment of malaria patients with the anti-malarial drug primaquine or other 8-
aminoquinolines may be associated with potential haemolytic anaemia. The aim of the present study was to
investigate the prevalence of G6PD variants in Thai population who resided in malaria endemic areas (western,
northern, north-eastern, southern, eastern and central regions) of Thailand, as well as the Burmese population who
resided in areas along the Thai-Myanmar border.
Methods: The ten common G6PD variants were investigated in dried blood spot samples collected from 317 Thai
(84 males, 233 females) and 183 Burmese (11 males, 172 females) populations residing in malaria endemic areas of
Thailand using PCR-RFLP method.
Results: Four and seven G6PD variants were observed in samples collected from Burmese and Thai population,
with prevalence of 6.6% (21/317) and 14.2% (26/183), respectively. Almost all (96.2%) of G6PD mutation samples
collected from Burmese population carried G6PD Mahidol variant; only one sample (3.8%) carried G6PD Kaiping
variant. For the Thai population, G6PD Mahidol (8/21: 38.1%) was the most common variant detected, followed by
G6PD Viangchan (4/21: 19.0%), G6PD Chinese 4 (3/21: 14.3%), G6PD Canton (2/21: 9.5%), G6PD Union (2/21: 9.5%),
G6PD Kaiping (1/21: 4.8%), and G6PD Gaohe (1/21: 4.8%). No G6PD Chinese 3, Chinese 5 and Coimbra variants
were found. With this limited sample size, there appeared to be variation in G6PD mutation variants in samples
obtained from Thai population in different regions particularly in the western region.
Conclusions: Results indicate difference in the prevalence and distribution of G6PD gene variants among the Thai
and Burmese populations in different malaria endemic areas. Dosage regimen of primaquine for treatment of both
Plasmodium falciparum and Plasmodium vivax malaria may need to be optimized, based on endemic areas with
supporting data on G6PD variants. Larger sample size from different malaria endemic is required to obtain accurate
genetic mapping of G6PD variants in Burmese and Thai population residing in malaria endemic areas of Thailand.
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Glucose-6-phosphate dehydrogenase (G6PD) is a meta-
bolic enzyme that catalyses the first reaction in the pen-
tose phosphate pathway, providing reducing power to all
cells in the form of NADPH (reduced form of nicotina-
mide adenine dinucleotide phosphate). NADPH enables
cells to counterbalance oxidative stress triggered by oxi-
dant agents. The G6PD gene is located at the telomeric
region of the X chromosome (band Xq28), consisting of
13 exons and 12 introns. It encodes 515 amino acids
and a GC-rich (more than 70%) promoter region [1].
G6PD deficiency is common in malaria endemic
regions and is estimated to affect more than 400 million
people worldwide. It is a hereditary genetic defect,
which is one of the most prevalent polymorphisms and
enzymopathies in humans, particularly in males [2-4].
This genetic defect was discovered in 1956 when some
patients developed haemolytic anaemia after the dose of
the anti-malarial drug primaquine [5]. G6PD-deficient
erythrocytes are more susceptible to destruction by oxi-
dative stress than normal erythrocytes due to the lower
NADPH levels. Individuals with this genetic defect may
exhibit non-immune haemolytic anaemia in response to
a number of stimuli, most commonly infections or
exposure to certain medications or chemicals [6].
The geographical distribution of malaria is remarkably
similar to the world distribution of deficient G6PD var-
iants [7]. It is postulated that the high frequency of
G6PD deficiency has arisen because G6PD deficient var-
iants confer some protection or resistance against
malaria caused by Plasmodium falciparum and Plasmo-
dium vivax [8]. Significant selective advantage against
severe malaria has been reported in deficient individuals
and heterozygous female carriers of deficient alleles.
Malaria has also been implicated in the spreading of
deficient variants in malaria endemic areas. A number
of different G6PD deficient variants have reached poly-
morphic frequencies and each has a characteristic distri-
bution in parts of the world where malaria is currently
or was previously endemic. The mutations result in pro-
tein variants with different levels of enzyme activity that
are associated with a wide range of biochemical and
clinical phenotypes [9]. Approximately 140 mutations
affecting the gene coding sequence have been reported
[2,10], most of which are single-base substitutions lead-
ing to amino acid replacements. In Southeast Asia, a
large number of G6PD deficient variants have been
reported from various populations. G6PD Viangchan
and G6PD Mahidol are most prevalent in Thailand [11].
G6PD-Mahidol was reported as the dominant mutation
in Burmese population [12,13]. G6PD Viangchan was
found to be the most common variant in Laotians [12],
Malaysian Malays [14,15], Cambodians [16] and Vietna-
mese [17]. Apart from mutations that lead to enzyme
deficiency, several polymorphic sites in introns have
been identified, enabling the definition of G6PD haplo-
types [2]. Since malaria and G6PD deficiency share simi-
lar geographical distribution, treatment of malaria
patients with the anti-malarial drug primaquine or other
8-aminoquinolines may be associated with potential hae-
molytic anaemia. The aim of the present study was,
therefore, to investigate the prevalence of G6PD variants
in Thai population who resided in malaria endemic
areas (western, northern, north-eastern, southern, east-
ern and central regions) of Thailand, as well as the Bur-
mese population who resided along Thai-Burma border
in Mae Sot district, Tak province, Thailand.
Methods
Samples
The study was conducted during the year 2008 and
2009. Blood samples (100 μl each, collected onto What-
man No. 3 filter paper) were obtained from Thai and
Burmese individuals (both healthy subjects and patients
with malaria) residing in malaria endemic areas of Thai-
land. These included a total of 317 Thai (84 males, 233
females) including north (six samples), north-east (21
samples), south (seven samples), west (217 samples),
east (six samples) and central (60 samples) regions of
Thailand, and 183 Burmese populations (11 males, 172
females) who had residential areas along the Thai-
Myanmar border in Mae Sot district, Tak province,
Thailand (Figure 1). All samples were randomly col-
lected for genotyping of G6PD variants without any
screening of G6PD deficiency. The average age of all
subjects was 29 (range 15-45) years. The study was
approved by Ethics Committee of Ministry of Public
Health of Thailand. Informed consents for study partici-
pation were obtained from all subjects before study.
Analysis of G6PD variants
Genomic DNA was extracted from dried blood spot
samples using standard phenol - chloroform method
[18] with modification. Ten common G6PD variants
previously reported in Southeast Asia [19] were analysed
using PCR-RFLP analysis as previously described
[11,20]. These included G6PD Gaohe A95G, G6PD Chi-
nese 4 G392T, G6PD Mahidol G487A, G6PD Chinese 3
A493G, G6PD Coimbra C592T, G6PD Viangchan
G781A, G6PD Chinese 5 C1024T, G6PD Union C1360T
G6PD Canton G1376T, and G6PD Kaiping G1833A.
Polymerase chain reaction was performed to gener-
ate the PCR fragments of the ten variants under 1
cycle of 5 min at 94°C, then 35 cycles of 1 min at 94°
C, 1 min at 58°C, 1 min at 72°C, and final extension
at 72°C for 10 min of amplification condition. PCR
fragments were digested with appropriate enzymes
and analysed on a 3% agarose gel containing ethidium
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Nuchprayoon et al. [20,21]. The PCR amplification
was directly performed without the screening of G6PD
deficiency (Table 1).
Results
Based on PCR-RFLP analysis of ten non-synonymous
G6PD mutations, 47 out of 500 samples were found to
carry G6PD mutation variants. The prevalence of
Number of samples collected from Thai population in 6 regions of  Thailand
Northern region: 6 samples
Northeastern region :21 samples
Western region: 
217samples Eastern region:    
Kanchanaburi
,PDJHIURPKWWSZZZWUDQVSDUHQWFRPWKDL
217samples
Southern region : 7 samples
g
6 samples
Central region:    
60 samples
Figure 1 Number of sample collected from Thai populationin 6 regions of Thailand.
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were 6.6% (21/317) and 14.2% (26/183), respectively
(Table 2).
Table 3 shows allele frequency of each of the ten
G6PD variants in male and female Thai and Burmese
populations. Out of 26 G6PD mutations samples in Bur-
mese population (24 females, two males), G6PD Mahi-
dol was found at a high frequency of 96.2% (25/26), of
which 8% (2/25) and 92% (23/25) were hemizygous
males and heterozygous females, respectively. Only one
heterozygous female sample (3.8%, 1/26) carried G6PD
Kaiping variant. The allele frequency of Mahidol variant
in males and females were 0.18 and 0.07, respectively
(Table 3).
For the Thai population, seven G6PD allelic variants
were observed among 21 (14 females, seven males)
G6PD mutations samples. The most common genotype
was G6PD Mahidol variant [38.1% (8/21)], of which
37.5% (3/8) and 62.5% (5/8) were males and heterozy-
gous females, respectively (Table 1). The allele frequency
of Mahidol variant in males and females were 0.04 and
0.01, respectively (Table 1). G6PD Viangchan was found
at the frequency of 19.0% (4/21), with 25% (1/4) males
(allele frequency 0.01) and 75% (3/4) heterozygous
females (allele frequency 0.006). G6PD Chinese 4 was
found at the frequency of 14.3% (3/21), with 100% (3/3)
heterozygous females (allele frequency 0.006). G6PD
Canton was found at the frequency of 9.5% (2/21),
Table 1 Restriction enzymes and result of genetic polymorphisms of G6PD mutation variants
G6PD Variant cDNA
Nucleotide
Substitution
Amino acid Substitution Restriction enzyme Results (bp)
Gaohe 95 A > G 32 His > Arg MluI N 198, M 174+24
Chinese 4 392 G > T 131 Gly > Val BstEII N 188+15, M 203
Mahidol 487 G > A 163 Gly > Ser HindIII N 104, M 82+22
Chinese 3 493 A > G 165 Asn > Asp AvaII N 120+11, M 87+33+11
Coimbra 592 C > T 198 Arg > Cys PstI N 157+83, M 157+63+20
Viangchan 871 G > A 291 Val > Met XbaI N 126, M 106+20
Chinese5 1024 C > T 342 Leu > Phe MboII N 187, M 150+37
Union 1360 C > T 454 Arg > Cys HhaI N 142+45+27, M 187+27
Canton 1376 C > T 459 Arg > Leu AflII N 214, M 194+20
Kaiping 1388 G > A 463 Arg > His NdeI N 227, M 206+21
N normal digestion result
M mutant digestion result
Table 2 The prevalence of 10 glucose -6-phosphate dehydrogenase (G6PD) variants in Thai and Burmese populations
Name of
variant
cDNA
Nucleotide
Substitution
Amino acid
Substitution
Ref SNP ID Class Population Total
(N = 500)
Thai
(n = 317)
Burmese (n = 183)
Mahidol 487 G > A 163 Gly > Ser rs137852314 3 8 (2.5, 38.1%)[5: 3] 25 (13.7, 96.2%) [23: 2] 33(6.6, 70.2%)
Viangchan 871 G > A 291 Val > Met rs137852327 3 4 (1.3, 19.0%)[3: 1] 0 (0, 0) 4(0.8, 8.5%)
Chinese 4 392 G > T 131 Gly > Val rs137852341 3 3 (1.0, 14.3%)[3: 0] 0 (0, 0) 3(0.6, 6.4%)
Union 1360 C > T 454 Arg > Cys 2 2 (0.6, 9.5%)[1: 1] 0 (0, 0) 2(0.4, 4.3%)
Canton 1376 C > T 459 Arg > Leu rs72554665 3 2 (0.6, 9.5%)[0: 2] 0 (0, 0) 2(0.4, 4.3%)
Kaiping 1388 G > A 463 Arg > His rs72554664 2 1 (0.3, 4.8%)[1: 0] 1 (0.5, 3.8%)[1: 0] 2(0.4, 4.3%)
Gaohe 95 A > G 32 His > Arg rs137852340 3 1 (0.3, 4.8%)[1: 0] 0 (0, 0) 1(0.2, 2.0%)
Chinese 3 493 A > G 165 Asn > Asp rs137852331 2 0 (0, 0) 0 (0, 0) 0 (0, 0)
Chinese 5 1024 C > T 342 Leu > Phe rs137852342 3 0 (0, 0) 0 (0, 0) 0 (0, 0)
Coimbra 592 C > T 198 Arg > Cys rs137852330 2 0 (0, 0) 0 (0, 0) 0 (0, 0)
Total 21 (6.6,100%) [14:
7]
26 (14.2,100%) [24:
2]
47 (9.4,100%) [38:
9]
Variants are identified by their common names with the nucleotide and amino acid positions based on the Genbank sequence with the accession number
X03674 and the genomic numbers on sequence with accession number X55448[22]. Data are presented for each variant as numbers of individual positive
(population prevalence, prevalence relative to total G6PD positive samples) [n females: n males].
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Union was found at the frequency of 9.5% (2/21), with
50% males (allele frequency 0.01) and heterozygous
females (allele frequency 0.002). G6PD Kaiping and
Gaohe were found at the frequencies of 4.8% (1/21),
with 100% (1/1) heterozygous females (allele frequencies
0.002 for both variants). No G6PD Chinese 3, Chinese
5, and Coimbra variants were found. No samples were
positive for more than one assayed G6PD variant.
Based on results of this limited study sample size,
there appeared to be variation in G6PD mutation var-
iants in samples obtained from Thai population residing
in different regions. G6PD mutation variants were
detected in a total of 17 (17/217: 5.36%), 3 (3/14:
14.28%) and 1 (1/21: 4.76%) from samples collected
from the western, central and north-eastern region,
r e s p e c t i v e l y .N oG 6 P Dv a r i a n tw a sf o u n di ns a m p l e s
collected from the northern, eastern and southern
regions (6 samples for each region). Seven G6PD var-
iants were observed in samples from the west region, of
which Mahidol variant was the most predominant (8/17:
47.1%), followed by G6PD Chinese 4 (3/17: 17.6%),
G6PD Union (2/17: 11.8%), G6PD Viangchan (1/17:
5.9%), G6PD Gaohe (1/17: 5.9%), G6PD Kaiping (1/17:
5.9%), and G6PD Canton (1/17: 5.9%). The G6PD
Viangchan was the only variant found in samples col-
lected from the central region at the frequency of 5.56%
(3/14) and G6PD Canton was the only variant found in
north-east region at the frequency of 1/21: 4.76%.
Discussion
Numerous mutations in G6PD gene cause a deficiency
of this enzyme in erythrocytes [23]. According to the
level of enzyme activity, World Health Organization
classified variants of G6PD to five groups: Class I
(severe deficiency of the enzyme with chronic non-
spherocytic > haemolytic anaemia), Class II (severe defi-
ciency with enzyme activity < 10% of normal), Class III
(moderate deficiency with enzyme activity 10-60% of
normal), Class IV (very mild to none deficiency with
enzyme activity 60-100% of normal), and Class V
(increased enzyme activity) [2,22]. Among the high
prevalent variants, G6PD Coimbra, G6PD Chinese 3,
G6PD Union, and G6PD Kaiping are classified as Class
II variants. G6PD Mahidol, G6PD Viangchan G6PD
Chinese 4, G6PD Canton, G6PD Gaohe, and G6PD Chi-
nese 5 are classified as Class III variant [24].
There is the difference in the prevalence and distribu-
tion of G6PD gene variants among the Thai and Bur-
mese populations. In Burmese population, four G6PD
variants (Mahidol, Coimbra, Union and Canton) were
detected. Based on results of our study and those so far
published [13], the predominant G6PD variant was
G6PD Mahidol, which was found in almost all G6PD
variant samples (25/26: 96.2%). Than et al. reported the
prevalence of G6PD Mahidol of 17.5% (160/916), while
no carriers of the G6PD Viangchan mutation were
detected [25]. The study of Nuchprayoon et al. [21]
showed 6.7% (12/178) of the Burmese males who lived
in southern Myanmar carried G6PD Mahidol variant.
Higher diversity of G6PD variants was observed in the
Thai population compared to the Burmese population,
with seven SNPs assayed being polymorphic and the
most commonly identified was G6PD Mahidol. It was
noted that, with this limited sample size, no sample
positive for more than one assayed G6PD variant was
found. Distribution of G6PD-deficient variants also dif-
fered among regions. G6PD Mahidol variant (47.1%, 8/
17) was dominantly detected in G6PD mutation samples
collected from the western region, whereas the Chinese
4, Union, Viangchan, Gaohe, Kaiping and Canton var-
iants were found at low frequencies in this region.
G6PD Gaohe, G6PD Chinese 4, G6PD Canton, and
G6PD Kaiping are the common variants found in Chi-
nese [26]. Two cases of G6PD Union which is predomi-
nantly found in populations in the Philippines [27], and
Papua New Guinea [28], were also found in Thai popu-
lation in this study. These findings support a common
ancestry of the population and the theory of genetic
drift throughout Southeast Asia.
The results are in agreement with that reported pre-
viously by Panich [29] that G6PD Mahidol variant was
the major variant in Thai population. The average allele
frequency in Thailand is 12%, but with distinct local
Table 3 Allele frequency of G6PD variants in male and female Thai and Burmese populations
Population/Gender (N) G6PD variant allele frequency
Mahidol Viangchan Chinese 4 Union Canton Kaiping Gaohe
Thai
Male (84) 0.04 0.01 - 0.01 0.02 0.012 -
Female (233) 0.01 0.006 0.006 0.002 - 0.002 0.002
Burmese
Male (11) 0.18 - - - - - -
Female (172) 0.07 - - - - 0.003 -
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border particularly in the Mon, Burmese and Karen
populations [29]. In another report [11], G6PD Viang-
chan was found to be the most common mutation
(54%), followed by G6PD Canton (10%), G6PD Mahidol
(8%), G6PD Kaiping (5%), G6PD Union (2.6%), and
G6PD Chinese 5 (2.6%). Among 20 neonates with
hyperbilirubinaemia, G6PD Viangchan was also found at
the highest frequency (60%), followed by G6PD Canton
(10%), G6PD Mahidol, G6PD Union, and G6PD Kaiping
(5% each). This variation in the reported prevalence of
G6PD variants in Thailand is due to differences in study
population, study design (random or selected sample
collection), study areas under investigation and techni-
ques used for mutation analysis. This study focused on
the investigation of the ten major non-synonymous
mutations of G6PD variants, which were reported in
Thai and Burmese populations using PCR-RFLP techni-
que. Unlike gene sequencing, PCR-RFLP is very specific
for detection of each of the ten G6PD mutation variant
and therefore detection of new or other minor muta-
tions could be missing. With this limited sample size,
no G6PD mutation variant was found in study samples
obtained from the northern, eastern and southern parts
of the country. Laosombat [19] reported ten different
G6PD variants in a total of 225 G6PD deficient indivi-
duals in the southern region (Songkla Province) of Thai-
land. The three most common variants were G6PD
Viangchan (31.3%), G6PD Kaiping (20.1%), and G6PD
Mahidol (17.2%). In addition, low prevalence of three
additional variants, i.e., G6PD Quing Yuan (G392T),
G6PD Mediterranean (C563T), and the new variant,
G6PD Songklanakarind (T196A) were identified.
Interestingly, the prevalence of G6PD deficiency and
malaria endemicity are thought to be correlated [30].
Several studies suggest that G6PD deficiency provides
protection against P. falciparum malaria among non-
immune adults [30-32]. This association between G6PD
and malaria was supported by population genetic ana-
lyses of the G6PD locus, which indicated that these
mutations may have recently risen in frequency in cer-
tain geographic regions as a result of positive selection.
According to this observation, prevalence of G6PD defi-
cient variants appeared to be high and variable in the
western region of Thailand where malaria incidence is
the highest of the country [33]. This may support the
link between incidence of G6PD deficiency and malaria
endemicity hypothesis [34]. Some previous studies also
detected a lower parasite count in G6PD-deficient
patients [35-38]. Despite numerous evidences on the
protection of P. falciparum malaria in G6PD deficiency
patients, the high failure rate following treatment with
standard anti-malarial regimen is still high [33]. Apart
from host genetic factor, parasite factor (e.g., resistant
genes) contributes more significantly to treatment
response [39]. Recent reports also suggest that the
malaria parasite can adapt itself to grow in these variant
erythrocytes by producing its own G6PD [40]. The para-
site’s G6PD enzyme is different to that of humans
because it is bifunctional, presenting 6-phosphoglucono-
lactonase (6PGL) activity in the molecule’s N-terminal
region [41]. Its expression in P. falciparum is an impor-
tant factor for parasite survival within the host cell. The
host-parasite co-evolutionary processes has been
reported to be associated with human’sc o d i n gg e n e
polymorphisms such as the haemoglobin variants (Hb E,
Hb C, Hb S, a-a n db-thalassemia), G6PD, membrane
receptor (Duffy protein), blood group proteins, HLA
(HLA-B53, DRB1*1302), and other immune regulatory
region with malaria resistance [42]. Louicharoen et al.
[8] has demonstrated that G6PD Mahidol variant has
been under strong positive selection for the last 1,500
years and that it reduces P. vivax density in humans.
The finding provides evidence that P. vivax has been a
driving force behind the selective advantage conferred
by the Mahidol mutation.
I nt h i ss t u d yw i t hl i m i t e ds a m p l es i z e ,t h em a j o r i t yo f
females were identified as heterozygous carriers of
G6PD mutations of all variants. These subjects are also
at risk of drug-induced haemolysis if the enzyme activity
is sufficiently low. Primaquine, an 8-aminoquinoline, is
the prototype of drugs that cause haemolysis in G6PD
deficiency. It is the only effective anti-malarial drug to
prevent relapses of the persistent liver forms of P. vivax
and P. ovale,a sw e l la st oi n t e r r u p tt h et r a n s m i s s i o no f
P. falciaprum gametocytes. The severity varies consider-
ably among affected individuals with G6PD variants and
the dose of primaquine given. The degree of haemolysis
in other variants of G6PD exposed to standard prima-
quine therapy (15-30 mg daily) varies markedly. Daily
d o s e so f1 5m go fp r i m a q u i n ef o r1 4d a y sf o l l o w i n ga
full course of chloroquine when prescribed to Thai
G6PD deficient patients where Mahidol variant is predo-
minant, are relatively safe [43]. A single dose of prima-
quine 45 mg and/or weekly for eight weeks has also
been found adequate and safe for the treatment of
patients with P. falciparum gametocytes and/or P. vivax
malaria ignoring these red cell G6PD enzyme deficient
variants in Myanmar. Administration of primaquine is
contraindicated during pregnancy irrespective of the
mother’s G6PD status [39]. Little is known about the
clinical efficacy of anti-malarials in individuals with dif-
ferent G6PD variants. In a more recent study conducted
in 2045 samples obtained from six African populations
( B u r k i n aF a s o ,G h a n a ,K e n y a ,N i g e r i a ,T a n z a n i a ,M a l i )
with acute uncomplicated falciaprum malaria [44],
G6PD genotype or phenotype had no influence on anti-
malarial efficacy of combination therapy with
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artesunate. There is also evidence that anti-malarial
drugs in patients with haemoglobinopathies exhibit dif-
ferent pharmacokinetic properties [45,46], and the stan-
dard doses of anti-malarials may be less efficacious [47].
For primaquine, there appears to be no difference in the
plasma concentrations or pharmacokinetics of prima-
quine between patients with normal G6PD and G6PD
deficiency [48].
Due to the risk of haemolysis in G6PD-deficient indi-
viduals, laboratory determination of the patient’sG 6 P D
status is recommended before prescribing primaquine.
The definitive diagnosis of G6PD deficiency is based on
the estimation of enzyme activity, by quantitative spec-
trophotometric analysis of the rate of NADPH produc-
tion from NADP [2]. For rapid population screening,
several semiquantitative methods have been applied,
such as the dye-decolouration test and fluorescent spot
tests, for identification of persons who will be at risk
from taking primaquine. In most of malaria endemic
countries including Thailand, such facilities may be lim-
ited. Policy for primaquine administration and optimal
dose regimen based on individual patient may not be
appropriate, but should be based on endemic area with
support of epidemiology data of local G6PD variants. It
would be interesting also to examine the haemolytic
effect of drugs upon different local variants. Testing of
new drugs for haemolytic potential should be done prior
to their introduction into areas with high frequencies of
the G6PD deficiency.
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